Evidence map›Paper›PMID 22870226›Full record

ArticlePloS one2012

Deep Panning: steps towards probing the IgOme.

Arie Ryvkin, Haim Ashkenazy, Larisa Smelyanski, Gilad Kaplan, Osnat Penn, Yael Weiss-Ottolenghi, Eyal Privman, Peter B Ngam, James E Woodward, Gregory D May and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Phage Display to Augment Biomaterial Function.International journal of molecular sciences · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Serological Number for Characterization of Circulating Antibodies.International journal of molecular sciences · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Biopanning data bank 2018: hugging next generation phage display.Database : the journal of biological databases and curation · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Arie RyvkinDepartment of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel.
Haim Ashkenazy
Larisa Smelyanski
Gilad Kaplan
Osnat Penn
Yael Weiss-Ottolenghi
Eyal Privman
Peter B Ngam
James E Woodward
Gregory D May
Callum Bell
Tal Pupko
Jonathan M Gershoni
Tel Aviv University · ILNational Center for Genome Resources · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolyclonal serum consists of vast collections of antibodies, products of differentiated B-cells. The spectrum of antibody specificities is dynamic and varies with age, physiology, and exposure to pathological insults. The complete repertoire of antibody specificities in blood, the IgOme, is therefore an extraordinarily rich source of information-a molecular record of previous encounters as well as a status report of current immune activity. The ability to profile antibody specificities of polyclonal serum at exceptionally high resolution has been an important and serious challenge which can now be overcome. METHODOLOGY/PRINCIPAL

findingsHere we illustrate the application of Deep Panning, a method that combines the flexibility of combinatorial phage display of random peptides with the power of high-throughput deep sequencing. Deep Panning is first applied to evaluate the quality and diversity of naïve random peptide libraries. The production of very large data sets, hundreds of thousands of peptides, has revealed unexpected properties of combinatorial random peptide libraries and indicates correctives to ensure the quality of the libraries generated. Next, Deep Panning is used to analyze a model monoclonal antibody in addition to allowing one to follow the dynamics of biopanning and peptide selection. Finally Deep Panning is applied to profile polyclonal sera derived from HIV infected individuals. CONCLUSIONS/SIGNIFICANCE: The ability to generate and characterize hundreds of thousands of affinity-selected peptides creates an effective means towards the interrogation of the IgOme and understanding of the humoral response to disease. Deep Panning should open the door to new possibilities for serological diagnostics, vaccine design and the discovery of the correlates of immunity to emerging infectious agents.

Indexed as

Antibody SpecificityPeptide LibraryAntibodies, MonoclonalB-LymphocytesHumansAntibodies, MonoclonalPeptide Library

Identifiers

PMID22870226
PMCPMC3409857
OpenAlexW1995107812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.